Tabula Rasa HealthCare (NASDAQ:TRHC) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Other research analysts have also issued reports about the company. Piper Jaffray Companies restated a “buy” rating and issued a $29.00 target price on shares of Tabula Rasa HealthCare in a research note on Tuesday, October 24th. UBS upped their target price on Tabula Rasa HealthCare from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, August 30th. Zacks Investment Research lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. ValuEngine upgraded Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Finally, Wells Fargo & Company lowered Tabula Rasa HealthCare from an “outperform” rating to a “market perform” rating and upped their target price for the company from $17.00 to $21.00 in a research note on Thursday, September 7th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $28.25.

Shares of Tabula Rasa HealthCare (NASDAQ TRHC) traded up $0.03 during midday trading on Friday, hitting $28.16. The company had a trading volume of 287,010 shares, compared to its average volume of 241,563. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. Tabula Rasa HealthCare has a twelve month low of $11.59 and a twelve month high of $36.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $33.27 million during the quarter, compared to analyst estimates of $31.76 million. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. Tabula Rasa HealthCare’s revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.06 earnings per share. equities analysts anticipate that Tabula Rasa HealthCare will post 0.05 EPS for the current year.

In other Tabula Rasa HealthCare news, insider Orsula V. Knowlton sold 8,000 shares of the stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $26.68, for a total transaction of $213,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Growth Fund 1Q Lp Originate sold 684,180 shares of the stock in a transaction on Monday, December 11th. The stock was sold at an average price of $25.85, for a total value of $17,686,053.00. The disclosure for this sale can be found here. Insiders have sold 1,099,180 shares of company stock valued at $28,435,203 over the last quarter. Corporate insiders own 45.80% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System acquired a new position in Tabula Rasa HealthCare during the third quarter worth $254,000. Allianz Asset Management GmbH acquired a new stake in shares of Tabula Rasa HealthCare in the third quarter valued at $3,801,000. Pier Capital LLC acquired a new stake in shares of Tabula Rasa HealthCare in the third quarter valued at $4,151,000. Schwab Charles Investment Management Inc. increased its stake in shares of Tabula Rasa HealthCare by 69.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 18,300 shares of the company’s stock valued at $490,000 after buying an additional 7,500 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of Tabula Rasa HealthCare by 79.8% in the third quarter. Wells Fargo & Company MN now owns 12,768 shares of the company’s stock valued at $341,000 after buying an additional 5,668 shares in the last quarter. Hedge funds and other institutional investors own 31.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Tabula Rasa HealthCare (TRHC) Downgraded by BidaskClub” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/16/tabula-rasa-healthcare-trhc-downgraded-by-bidaskclub.html.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.